Alytix develops bacteriophage-based products that target specific bacteria as safer and more ecological alternatives to conventional antibiotics.
Investment Funding
Last Funding Stage
Pre-Seed
Total Funding Amount
200.K
Last Funding Amount
200.K
Last Funding Date
05-07-2018
Startup Stage
Seed
Lead Investors
GRID EXPONENTIAL
People
Founders
Enzo Zamboni
Exequiel Dunand
Marcelo Salame
About
Alytix develops antibiotic alternatives to improve livestock health, reduce the unnecessary use of antibiotics, and increase environmental sustainability.
Products
Product
Bacteriophage-based antibiotic alternatives for animal health and farm use.
Star Product
Phage platform – the core technology used to build targeted antibacterial products.
Demo Product or Complete Product?
Product-development stage; public materials describe the technology and intended applications but provide limited launch detail.
Something missing or incorrect on this page? Help us enrich this information
